RxDoctor Payments Data

Gregory Faughnan, MD

Family Medicine · Camillus, NYNPI 1740770585

Payments from drug & device makers

$841in general payments, 2019–2025

Across 39 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$146
  • Abbott$108
  • AstraZeneca$59
  • GSK$54
  • Lilly USA, LLC$46
  • Amgen$42
  • plus $387 from 14 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$841 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$69,817
Medicare patients
234
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$46,243
JardianceEmpagliflozin33$42,979
MounjaroTirzepatide26$27,151
OzempicSemaglutide18$24,389
TrulicityDulaglutide20$21,178
FarxigaDapagliflozin Propanediol26$20,014
JanuviaSitagliptin Phosphate14$19,717
Repatha SureclickEvolocumab11$13,791
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$9,524
MultaqDronedarone Hcl11$8,343
Tresiba Flextouch U-200Insulin Degludec13$7,806
Varenicline Tartrate14$5,476
TrintellixVortioxetine Hydrobromide12$5,196
Bupropion XlBupropion Hcl30$3,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$46$48,32946 claims
PfizerEliquis$16$46,24357 claims
Novo NordiskOzempic$13$24,38918 claims
AstraZenecaFarxiga$59$20,01426 claims
MerckJanuvia$41$19,71714 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$5,19612 claims
AbbVieSynthroid$146$1,19813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Camillus

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →